Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Interest Income

Income earned on cash, deposits, and investments held by the company.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $2.19M fell 43.2% year over year, ahead of the -45.9% change in trailing-twelve-month interest income. Sequentially, it fell 18.0% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.

Context

  • Interest income amounted to 36333.3% of revenue in FY2025, down 3122.4 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -43.2% holds above the trailing-twelve-month pace of -45.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.19M-18.0% QoQ
Last fiscal yearDec 2025
$13.08M-45.7% YoY
LTMMar 2026
$11.41M-45.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.2%——
1 year-45.7%——
3-year CAGR+22.9%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
13.08M USD
Year-over-year change
-45.7%
4-year CAGR
+83.1%

Interest Income vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.9% is the 7th highest of 9, against a peer median of -39.2%.
  • Interest income amounts to 36812.9% of revenue for LYEL, versus a peer median of 4.8%.
LYEL Competitors
Interest Income for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$17.35M USD-14.3%+61.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$11.41M USD-45.9%+22.9%36812.9%
AMRNAmarin Corporation plcLTM Mar 2026$10.41M USD-19.3%+56.7%4.8%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$8.6M USD-44.4%+152.5%—
CABACabaletta Bio, Inc.LTM Mar 2026$5.62M USD-34.1%+73.0%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.91M USD-45.8%+12.3%—
GNLXGenelux CorporationLTM Mar 2026$1.99M USD+30.9%—24812.5%
ACIUAC Immune S.A.LTM Mar 2026CHF 1.36M CHF-58.3%+200.1%36.6%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD—+148.8%0.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
EDITEditas Medicine, Inc.LTM Mar 2026-$1.51M USD-112.9%+14.6%3.9%
Peer median (excluding LYEL) —-39.2%+67.3%4.8%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.